Peter Ordentlich - Jul 29, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Scientific Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Jul 29, 2022
Transactions value $
-$464,086
Form type
4
Date filed
8/26/2022, 04:14 PM
Previous filing
Feb 3, 2022
Next filing
Dec 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Other $3.74K +265 $14.12 265 Jul 29, 2022 Direct F1
transaction SNDX Common Stock Options Exercise $144K +22.8K +8621.13% $6.32 23.1K Aug 24, 2022 Direct
transaction SNDX Common Stock Sale -$572K -22.8K -98.85% $25.04 265 Aug 24, 2022 Direct F2, F3
transaction SNDX Common Stock Options Exercise $13.7K +2.15K +812.83% $6.35 2.42K Aug 24, 2022 Direct
transaction SNDX Common Stock Sale -$53.9K -2.15K -89.05% $25.04 265 Aug 24, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -2.15K -100% $0.00* 0 Aug 24, 2022 Common Stock 2.15K $6.35 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -22.8K -100% $0.00* 0 Aug 24, 2022 Common Stock 22.8K $6.32 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 265 shares by the Reporting Person on 07/29/2022 pursuant to the Issuer's Employee Stock Purchase Plan.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,647 options to purchase shares of common stock that are vested and immediately exercisable and a total of 148,194 options to purchase shares of common stock that have not yet vested.
F3 The sale prices ranged from $25.00 to $25.18.
F4 This option is fully vested.